Fungal Nail Infections (Onychomycosis): A Never-Ending Story?
article has not abstract
Vyšlo v časopise:
Fungal Nail Infections (Onychomycosis): A Never-Ending Story?. PLoS Pathog 10(6): e32767. doi:10.1371/journal.ppat.1004105
Kategorie:
Pearls
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.ppat.1004105
Souhrn
article has not abstract
Zdroje
1. HavlickovaA, CzaikaVA, FriedrichM (2008) Epidemiological trends in skin mycoses worldwide. Mycoses 51 S4: 2–15.
2. HanekeE, RoseeuwD (1999) The scope of onychomycosis: epidemiology and clinical features. Int J Dermatol 38 Suppl 2: 7–12.
3. OgasawaraY (2003) Prevalence and patient's consciousness of tinea pedis and onychomycosis. Nihon Ishinkin Gakkai Zasshi 44: 253–260.
4. GhannoumMA, HajjehRA, ScherR, KonnikovN, GuptaAK, et al. (2000) A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol 43: 641–648.
5. ScherRK (1994) Onychomycosis is more than a cosmetic problem. Br J Dermatol 130: 15.
6. GuptaAK, JainHC, LyndeCW, MacDonaldP, CooperEA, et al. (2000) Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter Canadian survey of 15,000 patients. J Am Acad Dermatol 43: 244–248.
7. FaergemannJ, CorreiaO, NowickiR, RoBI (2005) Genetic predisposition - understanding underlying mechanisms of onychomycosis. J Eur Acad Dermatol Venerol 19: 17–19.
8. LanternierF, PathanS, VincentQB, LiuL, CypowyjS, etal (2013) Deep dermatophytosis and inherited CARD9 deficiency. N Engl J Med 369: 1704–1714.
9. SaunteDM, HolgersenJB, HaedersdalM, StraussG, BitschM, et al. (2006) Prevalence of toe nail onychomycosis in diabetic patients. Acta Derm Venerol 86: 425–428.
10. NenoffP, Ginter-HanselmayerG, TietzHJ (2012) Fungal nail infections - an update: Part 1 - Prevalence, epidemiology, predisposing conditions, and differential diagnosis. Hautarzt 63: 30–38.
11. ScherRK, BaranR (2003) Onychomycosis in clinical practice: factors contributing to recurrence. Br J Dermatol 149: 5–9.
12. ArreseJE, Pierard-FranchimontC, PierardGE (1996) Fatal hyalohyphomycosis following Fusarium onychomycosis in an immunocompromised patient. Am J Dermatopathol 18: 196–198.
13. AlyR (1994) Ecology and epidemiology of dermatophyte infections. J Am Acad Dermatol 31: S21.
14. GhannoumMA, MukherjeePK, WarshawEM, EvansS, KormanNJ, et al. (2013) Molecular analysis of dermatophytes suggest spread of infection among household members. Cutis 91: 237–246.
15. ElewskiB, TavakkolA (2005) Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality. Ther Clin Risk Manag 1: 299–306.
16. TostiA, PiracciniBM, LorenziS (2000) Onychomycosis caused by nondermatophyte molds: clinical features and response to treatment of 59 cases. J Am Acad Dermatol 42: 217–224.
17. BlueCross BlueShield of Northeastern New York (2006 November 28) Drug Therapy Guidelines: Antifungal Agents Lamisil (terbinafine), Sporanox (itraconazole), Penlac (ciclopirox), Vfend (voriconazole). Drug P&T Newsletter.
18. LauharantaJ (1992) Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly. Clin Exp Dermatol 17: 41–43.
19. GhannoumMA, LongL, PfisterWR (2009) Determination of the efficacy of terbinafine hydrochloride nail solution in the topical treatment of dermatophytosis in a guinea pig model. Mycoses 52: 35–43.
20. FaergemannJ, ZehenderH, MilleriouxL (1994) Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails and after 250 mg terbinafine orally once daily for 7 and 14 days. Clin Exp Dermatol 19: 121–126.
21. OsborneCS, LeitnerI, FavreB, RyderNS (2004) Antifungal drug response in an in vitro model of dermatophyte nail infection. Med Mycol 42: 159–163.
22. GhannoumM, IshamN, HerbertJ, HenryW, YurdakulS (2011) Activity of TDT 067 (Terbinafine in Transfersome) against Agents of Onychomycosis, as Determined by Minimum Inhibitory and Fungicidal Concentrations. J Clin Microbiol 49: 1716–1720.
23. AlleyMR, BakerSJ, BeutnerKR, PlattnerJ (2007) Recent progress on the topical therapy of onychomycosis. Expert Opin Investig Drugs 16: 157–167.
24. GhannoumM, IshamN, CatalanoV (2013) A Second Look at Efficacy Criteria for Onychomycosis: Clinical and Mycological Cure. Br J Dermatol. E-pub ahead of print. doi:10.1111/bjd.12594
25. GuptaAK, SimpsonFC (2013) Laser therapy for onychomycosis. J Cutan Med Surg 17: 301–307.
26. HarrisF, PierpointL (2012) Photodynamic therapy based on 5-aminolevulinic acid and its use as an antimicrobial agent. Med Res Rev 32: 1292–1327.
27. Delgado-CharroMB (2012) Iontophoretic drug delivery across the nail. Expert Opin Drug Deliv 9: 91–103.
28. SilvaJL, DoimoG, FariaDP (2011) The use of high frequency waves to treat onychomycosis: preliminary communication of three cases. An Bras Dermatol 86: 598–600.
29. AbadiD, ZdericV (2011) Ultrasound-mediated nail drug delivery system. J Ultrasound Med 30: 1723–1730.
30. YazdanparastSA, BartonRC (2006) Arthroconidia production in Trichophyton rubrum and a new ex vivo model of onychomycosis. J Med Microbiol 55: 1577–1581.
31. BradleyM, LeidichS, IshamN, ElewskiB, GhannoumM (1999) Antifungal susceptibilities and genetic relatedness of serial Trichophyton rubrum isolates from patients with onychomycosis of the toenail. Mycoses 42: 105–110.
32. GhannoumMA, IshamN, LongL (2012) Optimization of an infected shoe model for the evaluation of an ultraviolet shoe sanitizer device. J Am Podiatr Med Assoc 102: 309–313.
Štítky
Hygiena a epidemiológia Infekčné lekárstvo LaboratóriumČlánok vyšiel v časopise
PLOS Pathogens
2014 Číslo 6
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Očkování proti virové hemoragické horečce Ebola experimentální vakcínou rVSVDG-ZEBOV-GP
- Koronavirus hýbe světem: Víte jak se chránit a jak postupovat v případě podezření?
Najčítanejšie v tomto čísle
- Fungal Nail Infections (Onychomycosis): A Never-Ending Story?
- Profilin Promotes Recruitment of Ly6C CCR2 Inflammatory Monocytes That Can Confer Resistance to Bacterial Infection
- Cytoplasmic Viral RNA-Dependent RNA Polymerase Disrupts the Intracellular Splicing Machinery by Entering the Nucleus and Interfering with Prp8
- HopW1 from Disrupts the Actin Cytoskeleton to Promote Virulence in Arabidopsis